Affimed (NASDAQ:AFMD) Sees Significant Growth in Short Interest

Affimed (NASDAQ:AFMD) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 921,900 shares, an increase of 194.3% from the May 31st total of 313,200 shares. Approximately 7.1% of the shares of the company are short sold. Based on an average daily volume of 674,600 shares, the short-interest ratio is currently 1.4 days.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AFMD. Wells Fargo & Company cut their price objective on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, April 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Monday, April 1st. Laidlaw lifted their price objective on shares of Affimed from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Affimed in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.67.

Institutional Trading of Affimed

A number of institutional investors and hedge funds have recently modified their holdings of AFMD. Vestal Point Capital LP bought a new stake in Affimed during the 4th quarter valued at approximately $341,000. BNP Paribas Financial Markets boosted its position in shares of Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after acquiring an additional 163,162 shares in the last quarter. EWA LLC bought a new stake in Affimed in the fourth quarter valued at about $89,000. Finally, abrdn plc acquired a new position in Affimed in the fourth quarter worth about $130,000. 30.82% of the stock is currently owned by institutional investors and hedge funds.

Affimed Stock Performance

Affimed stock traded down $0.10 during mid-day trading on Thursday, hitting $5.47. 68,701 shares of the company’s stock were exchanged, compared to its average volume of 399,959. Affimed has a 1-year low of $2.23 and a 1-year high of $8.95. The stock has a 50 day moving average of $5.49 and a two-hundred day moving average of $5.50. The company has a current ratio of 3.06, a quick ratio of 3.06 and a debt-to-equity ratio of 0.12.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.